The unprecedented and rapid spread of SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) has motivated the need for a rapidly producible and scalable vaccine. Here, we developed a synthetic soluble SARS-CoV-2 spike (S) DNA-based vaccine candidate, GX-19. In mice, immunization with GX-19 elicited not only S-specific systemic and pulmonary antibody responses but also Th1-biased T cell responses in a dose-dependent manner. GX-19-vaccinated nonhuman primates seroconverted rapidly and exhibited a detectable neutralizing antibody response as well as multifunctional CD4+ and CD8+ T cell responses. Notably, when the immunized nonhuman primates were challenged at 10 weeks after the last vaccination with GX-19, they had reduced viral loads in contrast to non-vaccinated primates as a control. These findings indicate that GX-19 vaccination provides a durable protective immune response and also support further development of GX-19 as a vaccine candidate for SARS-CoV-2.
【저자키워드】 COVID-19, DNA vaccine, 【초록키워드】 SARS-CoV-2, Vaccine, vaccination, Antibody Response, immunization, Spread, mice, vaccine candidate, T cell response, CD8+ T cell, Neutralizing antibody response, SARS-CoV-2 spike, Support, dose-dependent manner, protective immune response, CD4+, responses, immunized, detectable, exhibited, provide, seroconverted, elicited, multifunctional, reduced viral load, 【제목키워드】 SARS-CoV-2, spike, DNA, primate,